Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.88 [0.72, 1.08] | | < 1 | | 0% | 1 study (1/-) | 89.2 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.02 [0.84, 1.24] | | < 1 | | 0% | 1 study (1/-) | 42.3 % | NA | not evaluable | | important | - |
DCR | 1.00 [0.63, 1.58] | | > 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.05 [0.66, 1.68] | | > 1 | | 0% | 1 study (1/-) | 58.1 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.45 [0.21, 0.94] | | < 1 | | 0% | 1 study (1/-) | 98.3 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.89 [0.62, 1.28] | | < 1 | | 0% | 1 study (1/-) | 73.3 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.01 [0.52, 1.97] | | < 1 | | 0% | 1 study (1/-) | 48.4 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.97 [0.53, 1.77] | | < 1 | | 0% | 1 study (1/-) | 54.3 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.21 [0.80, 1.80] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.16 [0.56, 2.38] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.29 [0.19, 0.45] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.35 [0.21, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 8.22 [0.43, 156.41] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.91 [0.36, 2.28] | | < 1 | | 0% | 1 study (1/-) | 58.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 1.01 [0.02, 51.25] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.04 [0.00, 0.75] | | < 1 | | 0% | 1 study (1/-) | 98.4 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.50 [0.05, 5.60] | | < 1 | | 0% | 1 study (1/-) | 71.0 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.17 [0.01, 3.35] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
Dermatitis acneiform TRAE (grade 3-4) | 1.01 [0.02, 51.25] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.17 [0.01, 3.35] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.01 [0.14, 7.25] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.01 [0.02, 51.25] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 1.01 [0.06, 16.29] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.12 [0.01, 2.37] | | < 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.51 [0.02, 15.13] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 2.03 [0.07, 60.79] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.04 [0.00, 0.68] | | < 1 | | 0% | 1 study (1/-) | 98.6 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.50 [0.05, 5.60] | | < 1 | | 0% | 1 study (1/-) | 71.0 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.01 [0.02, 51.25] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.01 [0.02, 51.25] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 2.03 [0.07, 60.79] | | < 1 | | 0% | 1 study (1/-) | 34.4 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.01 [0.06, 16.29] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |